Log in

NASDAQ:TRIB - Trinity Biotech Stock Price, Forecast & News

+0.04 (+4.17 %)
(As of 02/23/2020 05:31 AM ET)
Today's Range
Now: $1.00
50-Day Range
MA: $1.10
52-Week Range
Now: $1.00
Volume42,536 shs
Average Volume266,101 shs
Market Capitalization$24.04 million
P/E RatioN/A
Dividend YieldN/A
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:TRIB



Sales & Book Value

Annual Sales$97.04 million
Cash Flow$0.28 per share
Book Value$1.83 per share


Net Income$-22,090,000.00


Market Cap$24.04 million
Next Earnings Date3/5/2020 (Estimated)

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) posted its quarterly earnings data on Wednesday, October, 16th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.02. The business earned $24.59 million during the quarter. Trinity Biotech had a negative return on equity of 10.96% and a negative net margin of 31.56%. View Trinity Biotech's Earnings History.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Trinity Biotech.

Has Trinity Biotech been receiving favorable news coverage?

Media headlines about TRIB stock have trended very negative on Sunday, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trinity Biotech earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Trinity Biotech.

Who are some of Trinity Biotech's key competitors?

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Netflix (NFLX), QUALCOMM (QCOM), Celgene (CELG), Expedia Group (EXPE), Illumina (ILMN), Novavax (NVAX), Opko Health (OPK), Supernus Pharmaceuticals (SUPN) and Pfizer (PFE).

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the folowing people:
  • Mr. Ronan O'Caoimh, Co-Founder, Chairman & CEO (Age 63)
  • Mr. Kevin Tansley, CFO, Company Sec. & Exec. Director (Age 48)
  • Dr. James Walsh, Exec. Director (Age 61)

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Hunter Associates Investment Management LLC (6.15%), Heartland Advisors Inc. (2.74%), First Wilshire Securities Management Inc. (2.20%) and Adirondack Research & Management Inc. (1.47%).

Which institutional investors are selling Trinity Biotech stock?

TRIB stock was sold by a variety of institutional investors in the last quarter, including First Wilshire Securities Management Inc., Adirondack Research & Management Inc. and Hunter Associates Investment Management LLC.

Which institutional investors are buying Trinity Biotech stock?

TRIB stock was bought by a variety of institutional investors in the last quarter, including Heartland Advisors Inc..

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $1.00.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $24.04 million and generates $97.04 million in revenue each year. View Additional Information About Trinity Biotech.

What is Trinity Biotech's official website?

The official website for Trinity Biotech is http://www.trinitybiotech.com/.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]

MarketBeat Community Rating for Trinity Biotech (NASDAQ TRIB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  245 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: 52- Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel